AptarGroup Sales Rise 6%; Adjusted EPS Reaches $1.52
AptarGroup reported Q3 2026 sales of $1.02B, up 6% YoY, with adjusted EPS at $1.52. Core sales rose 5%, while net income fell to $32.6M from $127.9M YoY due to a $60.4M after-tax impact from deconsolidating its Russian subsidiary. CEO Gael Touya highlighted priorities including customer relationships and innovation.
How this was made
The 30-second read
Why it matters
The quarter combines growth in core sales with a one-off reported earnings hit from deconsolidation, while adjusted profitability (EBITDA margin) declined versus the prior-year quarter.
Market read
Traders can reassess near-term earnings power by separating adjusted results from reported EPS distortion, while monitoring margin trajectory and ongoing Russia exposure.
What to watch
North America beauty remains challenged and emergency medicine destocking partially offset strengths, which could cap near-term multiple expansion despite headline EPS beat.
Background
AptarGroup deconsolidated its Russian subsidiary after a governmental decree placed it under external administration and Aptar lost control.
Ticker impact
AptarGroup reported Q3 2026 net sales of $1.019B (+6% YoY) and adjusted diluted EPS of $1.52, plus a Russian subsidiary deconsolidation impact.
Likely modest upside bias as investors focus on sales growth and adjusted EPS, while keeping an overhang on margin pressure and Russia-related accounting effects.
The article provides concrete quarterly figures (sales, adjusted EPS, EBITDA margin) and a specific one-off accounting driver ($60.4M after-tax impact) that can separate underlying performance from reported earnings.
Market effects
Signals demand resilience in pharma and beauty end-markets, but highlights ongoing volatility from geopolitical exposure and margin normalization.
Russia deconsolidation underscores continued operational and reporting uncertainty tied to external administration risk.
May influence sentiment toward diversified drug-delivery and dispensing suppliers with emerging-market/geopolitical exposure.
Counterpoint
Adjusted EPS strength may not translate into cash earnings quality, given the drop in adjusted EBITDA margin and the large Russia-related accounting disruption.
Key entities
- companyAptarGroup, Inc.
Reported Q3 2026 sales growth and adjusted EPS, alongside Russia deconsolidation accounting impact.
- eventRussian subsidiary deconsolidation
Government decree led to external administration, Aptar lost control, and the quarter included a $60.4M after-tax impact.
